| US 7,495,011 B2 | ||
| Anti-coronavirus drug | ||
| Nobutaka Fujii, Otsu (Japan); and Naoki Yamamoto, Tokyo (Japan) | ||
| Assigned to aRigen Pharmaceuticals, Inc., Tokyo (Japan) | ||
| Appl. No. 10/564,557 PCT Filed Jul. 14, 2004, PCT No. PCT/JP2004/010352 § 371(c)(1), (2), (4) Date Mar. 28, 2006, PCT Pub. No. WO2005/004868, PCT Pub. Date Jan. 20, 2005. |
||
| Claims priority of application No. 2003-274886 (JP), filed on Jul. 15, 2003. | ||
| Prior Publication US 2006/0223847 A1, Oct. 05, 2006 | ||
| Int. Cl. C07D 217/02 (2006.01); A61K 31/47 (2006.01) | ||
| U.S. Cl. 514—310 [546/146] | 3 Claims |
1. A method for treating SARS in a patient in need of treatment using an anti-SARS-associated coronavirus agent comprising
as the active ingredient a compound represented by formula (5).
 or a pharmaceutically acceptable salt thereof.
|